Sat.Feb 05, 2022 - Fri.Feb 11, 2022

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015.

Vaccines 132
article thumbnail

J.&J. Pauses Production of Its Covid Vaccine Despite Persistent Need

NY Times

A crucial Johnson & Johnson plant has stopped making its Covid vaccine, though the company says it has millions of doses in inventory.

Vaccines 143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ViiV Healthcare long-acting HIV treatment secures FDA approval

Outsourcing Pharma

The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.

110
110
article thumbnail

Top 3 Things to Know About Engaging Oncologists in 2022

Pharma Marketing Network

Experts from top life sciences companies discussed strategies for more effectively engaging oncologists at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about engaging oncologists in 2022: 1. Lead with clinical education. It’s no longer enough to build brand awareness, according to the panelists.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Regenxbio expands MPS I gene therapy trial after first look at data

pharmaphorum

Data from the first patients enrolled into Regenxbio’s trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the first signs of clinical activity. The results come from five patients enrolled in the biotech’s ingoing phase 1/2 study of RGX-111 – which uses an adeno-associated viral vector (AAV9) to deliver a gene coding for an enzyme that is deficient in MPS I patients – plus a single subject from an earl

article thumbnail

Two cases of ‘eye bleeding’ Lassa fever found in UK

Pharma Times

Rare viral haemorrhagic disease similar to Ebola surface in the East of England

131
131

More Trending

article thumbnail

Which pharmaceutical companies have the most drug patents in Cyprus?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Novo Nordisk gets NICE okay for obesity drug Wegovy

pharmaphorum

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. NICE has backed use of the Wegovy (semaglutide) for people with a body mass index (BMI) of 35 kg/m2 or more and at least one weight-related ailment – such as high blood pressure, high cholesterol or diabetes – as part of a weight management programme involving exercise and a reduce-calorie

Labelling 105
article thumbnail

Not so NICE: cancer patients miss out on innovative new treatments

Pharma Times

Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes

106
106
article thumbnail

Breast cancer tops list of most studied disease in 2021: Phesi

Outsourcing Pharma

The companyâs analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.

112
112
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

F.D.A Delays Review of Pfizer’s Covid Vaccine for Children Under 5

NY Times

The agency will wait for data on whether three doses of Pfizer-BioNTech’s Covid vaccine are effective in young children after new, disappointing data.

article thumbnail

AI Marketing for Pharma – The time to rise is Now!

pharmaphorum

The digitalisation that we all experience daily has affected the way we engage with stakeholders and patients. But how can we make Customer Engagement effective, and how can we leverage technologies like AI and Marketing Automation to their best potential? The key to success lies in implementing a digital health ecosystem , in order to support the shift from an organization-centric model to a customer-centric model by using digital platforms.

105
105
article thumbnail

Clear Connections for Equitable Medication Access

Drug Channels

Today’s guest post comes from John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds. John discusses some of the findings in CoverMyMeds’ recently published report on medication access. He describes patient-centric, data-driven solutions to help patients access, afford, and adhere to their therapies. To learn more, download CoverMyMeds’ 2022 Medication Access Report.

87
article thumbnail

Let it Flow: COVID-19 LFT passes UK government assessment

Pharma Times

Sustainable lateral flow test kits developed in Birmingham reduce plastic and boost self-testing through ease of use

103
103
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Angry Customers, More Work and Longer Hours Strain Pharmacists

NY Times

Pharmacists and technicians, who have played a critical role in administering Covid-19 tests and vaccines, say they are burned out nearly two years into the pandemic.

article thumbnail

Do skills gaps and the COVID brain drain threaten digital transformation?

pharmaphorum

With staff shortages and digital skill gaps being experienced across the spectrum of healthcare, from CROs and pharma to providers, the people-led sector is facing a personnel challenge that could threaten the potential of digital transformation. The healthcare ecosystem may be the natural beneficiary of recent advances in data collection and analysis, but that’s no use without the staff to develop and implement solutions.

article thumbnail

Evolution of clinical trial data calls for evolved response: ICON

Outsourcing Pharma

In the first of a two-part series, leaders from the CRO discuss how study data has progressed in recent years and how trial teams can keep up effectively.

90
article thumbnail

Study shows psychosocial effects of peanut allergy

Pharma Times

Research demonstrates that people who live with peanut allergies face isolation and discrimination

111
111
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

C.D.C. Proposes New Guidelines for Treating Pain, Including Opioid Use

NY Times

The agency threw out previous recommended limits on doses but encouraged “nonopioid therapies” wherever possible.

103
103
article thumbnail

Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

pharmaphorum

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. The massive windfall revenues will drive its sales up towards the $100 billion mark – it’s estimating a range of $98 to $102 billion – up from $81.3 billion in 2021, which was almost twice revenues in the prior year.

article thumbnail

Drug Pricing Transparency Congress

Drug Channels

Drug Pricing Transparency Congress. Hybrid Event March 28-29, 2022 | Philadelphia, PA www.informaconnect.com/drug-pricing-transparency. Don’t miss the Drug Pricing Transparency Congress on March 28-29, 2022! You'll be part of the important discussions on how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices.

article thumbnail

New management: Promising drug for people living with obesity

Pharma Times

NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%

113
113
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

The Next Vaccine Debate: Immunize Young Children Now, or Wait?

NY Times

It’s not clear whether three doses of the Pfizer-BioNTech vaccine will adequately protect young children. But the F.D.A. may authorize the first two doses anyway.

article thumbnail

FDA fast tracks Bayer’s oral anticoagulant asundexian

pharmaphorum

The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs. Asundexian (also known as BAY2433334) will be given a speedy review by the US regulator as a secondary preventative treatment for people with ischaemic stroke, specifically those with non- cardioembolic risk factors like narrowed arteries.

article thumbnail

TFF completes enrollment in early-phase trial of inhaled COVID-19 therapy

Outsourcing Pharma

The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.

article thumbnail

Need for Speed: Kidney cancer patients waiting three times longer

Pharma Times

Greater urgency for kidney cancer treatments as 40% of UK patients wait 84 days for a diagnosis

110
110
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

F.D.A. Clears Monoclonal Antibody Drug From Eli Lilly

NY Times

The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.

71
article thumbnail

Empowering rare disease patient advocacy organisations with data

pharmaphorum

Komodo Health’s president and co-founder, Web Sun, tells us about his company’s new partnership with the Chan Zuckerberg Initiative (CZI) to improve early diagnosis and advance research of rare diseases by providing CZI’s Rare as One Network healthcare data and software. Though 7,000 rare diseases exist that affect 400 million people globally, a lack of understanding of these diseases can cause a delay in diagnosis and, in turn, treatment.

101
101
article thumbnail

Four Reasons Why PBMs Gain As Maximizers Overtake Copay Accumulators

Drug Channels

More than four years ago, I warned about the emerging trend of copay accumulators and outlined the costly consequences for patients. The latest data reveal that copay accumulator adjustment programs are now in the word list for a growing share of pharmacy benefit designs. What’s more, adoption of copay maximizers now exceeds that of copay accumulators.

88
article thumbnail

Pandemic, practice and policymaking: European-wide review of community pharmacies

Pharma Times

Extensive research into pharmacy responses across Europe during the pandemic yields several recommendations

article thumbnail

FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China

NY Times

The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights the high cost of immunotherapy.

58